Dolutegravir sodiumMeSH concept

https://www.has-sante.fr/jcms/p_3497014/fr/dovato-dolutegravir/lamivudine-antiretroviraux
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
lamivudine
dolutegravir sodium
dolutegravir
Dolutegravir Sodium/Lamivudine
hiv infections
HIV-1
adult
adolescent
lamivudine and dolutegravir
administration, oral
evaluation of the transparency committee
anti-retroviral agents

---
https://www.has-sante.fr/jcms/p_3445064/fr/triumeq-abacavir/dolutegravir-sodique/lamivudine-vih
2023
false
false
false
France
HIV-1
treatment outcome
insurance, health, reimbursement
administration, oral
adult
adolescent
child
hiv infections
lamivudine
drug combinations
abacavir sulfate
dolutegravir sodium
lamivudine, abacavir and dolutegravir
anti-hiv agents
abacavir, dolutegravir, and lamivudine drug combination
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3293335/fr/tivicay-dolutegravir-sodique
2021
false
false
false
France
hiv infections
adult
adolescent
child
treatment outcome
insurance, health, reimbursement
dolutegravir
teratogens
pregnancy
evaluation of the transparency committee
dolutegravir sodium
HIV integrase inhibitors
dolutegravir
heterocyclic compounds, 3-ring
oxazines
piperazines
pyridones

---
https://www.has-sante.fr/jcms/p_3293332/fr/triumeq-abacavir/dolutegravir-sodique/lamivudine
2021
false
false
false
France
treatment outcome
adult
adolescent
hiv infections
HIV-1
abacavir sulfate
dolutegravir sodium
lamivudine
lamivudine, abacavir and dolutegravir
anti-hiv agents
drug combinations
insurance, health, reimbursement
administration, oral
pregnancy
lamivudine
abnormalities, drug-induced
dolutegravir sodium
abacavir sulfate
neural tube defects
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3294118/fr/dovato-50-mg/300-mg-dolutegravir-sodique/-lamivudine
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
lamivudine and dolutegravir
drug combinations
administration, oral
lamivudine
dolutegravir sodium
adult
adolescent
hiv infections
HIV-1
anti-hiv agents
anti-hiv agents
dolutegravir sodium
teratogens
pregnancy
neural tube defects
abnormalities, drug-induced

---
https://www.has-sante.fr/jcms/p_3280958/fr/tivicay-dolutegravir-sodique-vih-pediatrique
2021
false
false
false
France
evaluation of the transparency committee
dolutegravir sodium
tivicay
dolutegravir

---
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay-dolutegravir-inhibiteur-de-l-integrase
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay
2017
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
drug resistance, viral
guidelines for drug use
child
continuity of patient care
human immunodeficiency virus i infection
Genotype drug resistance test
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64287253
2015
false
false
false
France
French
summary of product characteristics
evaluation of the transparency committee
package leaflet
lamivudine, abacavir and dolutegravir
lamivudine
abacavir sulfate
dolutegravir sodium
drug combinations
abacavir
dolutegravir
dideoxynucleosides
heterocyclic compounds, 3-ring

---
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay-50-mg-dolutegravir-inhibiteur-de-lintegrase
2014
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adult
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
clinical trials as topic
drug resistance, viral
guidelines for drug use
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
https://www.ema.europa.eu/medicines/human/EPAR/Triumeq
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
abacavir sulfate
abacavir sulfate
dolutegravir sodium
dolutegravir sodium
lamivudine
lamivudine
anti-hiv agents
anti-hiv agents
hiv infections
adolescent
adult
aged
administration, oral
tablets
lamivudine, abacavir and dolutegravir
HLA-B*57:01 antigen
genetic testing
drug hypersensitivity
reverse transcriptase inhibitors
reverse transcriptase inhibitors
HIV integrase inhibitors
HIV integrase inhibitors
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
abacavir
abacavir
HLA-B antigens
dideoxynucleosides
dideoxynucleosides

---